Drug intelligence / Profile preview

LY2403021

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY2403021 is a small molecule compound developed by Eli Lilly for therapeutic investigation, primarily in metabolic diseases. While detailed public information on its precise mechanism of action is limited, available clinical trial data indicate that it was studied as an orally administered agent in the context of type 2 diabetes mellitus. The drug was evaluated for its effects on glucose metabolism and cardiac electrophysiology, suggesting a potential role as a glucagon receptor antagonist or modulator. However, no definitive target or pathway has been publicly confirmed.

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on LY2403021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2403021.

Explore the full profile